Tempest Therapeutics, Inc.

TPST ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $7.7M $30.3M $39.2M $31.2M $51.8M $18.8M $62.5M $73.3M
Accounts Receivable
Inventory
Total Current Assets $8.3M $31.5M $40.4M $33.0M $69.0M $19.8M $71.1M $83.4M
Property, Plant & Equipment $605.0K $886.0K $840.0K $1.1M $1.1M $1.1M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $16.9M $41.5M $51.6M $46.1M $73.2M $22.9M $75.0M $84.1M
Liabilities
Accounts Payable $1.0M $2.5M $845.0K $1.1M $991.0K $1.1M $1.5M $2.0M
Total Current Liabilities $3.3M $14.2M $9.4M $7.3M $20.0M $3.2M $12.5M $9.8M
Long-Term Debt $0 $6.3M $10.4M $15.1M $61.0K $168.0K $383.0K
Total Liabilities $10.3M $22.4M $24.8M $28.0M $37.1M $4.9M $15.1M $11.0M
Stockholders' Equity
Retained Earnings $-233.4M $-207.1M $-165.3M $-135.8M $-100.1M $-71.8M $-208.7M $-164.1M
Total Stockholders' Equity $6.7M $19.1M $26.8M $18.1M $36.1M $-68.8M $-50.4M $71.0M
← Newer Page 1 of 2 Older →